Clinical trials: Severe ARDS
Acute Respiratory Distress Syndrome, COVID-19
Predictors of Severe COVID-19 Outcomes
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes…
- Trial name
- PRESCO (NCT04388813)
- Where
- 8 sites in United States
- Volunteers
- 494 people
- Sponsor
- Verily Life Sciences LLC
H1N1 Influenza
Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress Syndrome
Mannose-binding lectin (MBL) plays an important role in the innate immune response. In addition to activating the complement, MBL can induce cytokine production and contribute to a deleterious inflammatory response with severe…
- Trial name
- ARDS (NCT03641690)
- Testing
- Empirical antimicrobial therapy
- Where
- France
- Volunteers
- 97 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis…
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia
- Trial name
- NCT07492875
- Testing
- Nogapendekin alfa inbakicept (NAI), agenT-797
- Sponsor
- ImmunityBio, Inc.
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe)
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
- Trial name
- NCT04466098
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
ECMO Treatment
Clinical Studies of the Effects of Extracorporeal Membrane Oxygenation for Severe ARDS Mortality
Acute respiratory distress syndrome (acute respiratory distress syndrome, ARDS) fatality rate can be as high as 20% -41%, once progress is severe of ARDS, mortality rose to 90%, the main cause of death was refractory hypoxemia.
- Trial name
- NCT01677117
- Volunteers
- 25 people
- Sponsor
- Southeast University, China
ARDS, Human, COVID
Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease that has now been named COVID-19.
- Trial name
- COVIPOC (NCT04594668)
- Testing
- Senicapoc
- Where
- 4 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
Respiratory Infection, Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired…
- Conditions
- Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- TRICOVID (NCT05531149)
- Testing
- Trimodulin
- Where
- 64 sites in Argentina, Austria and 12 more
- Volunteers
- 107 people
- Sponsor
- Biotest
ARDS (Moderate or Severe), AHRF
STimulation to Activate RespIration
Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute…
- Conditions
- ARDS (Moderate or Severe), AHRF, Mechanically Ventilated ICU Patients
- Trial name
- STARI (NCT06832306)
- Testing
- Phrenic Nerve Stimulation
- Where
- 7 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Lungpacer Medical Inc.
Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome)
RECOMMEND Platform Trial
The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO) The main…
- Conditions
- Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome), Intensive Care Medicine, Cardiac Arrest (CA)
- Trial name
- RECOMMEND (NCT06526533)
- Testing
- Liberal RBC Transfusion, Restrictive RBC Transfusion
- Where
- 3 sites in Australia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
ARDS (Acute Respiratory Distress Syndrome)
Comparative Study Between Airway Pressure Release Ventilation and Pressure Regulated Volume Control (PRVC) in Protective Lung Strategy as a Recruitment Maneuver for Severe ARDS Mechanically Ventilated Patients Using Lung Ultrasound Score
The aim of this study is to elaborate on the effectiveness of recruitment maneuver by airway pressure release ventilation (APRV) as an open lung ventilatory strategy in comparison with PRVC mode in lung protective strategy…
- Trial name
- NCT07231107
- Testing
- Lung ultrasound
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Prone Position, Severe Acute Respiratory Syndrome Coronavirus 2
Evaluation of Sedation in COVID-19 ARDS
This study focuses on the evaluation of various factors repeatedly discussed in relation to the impaired sedation of intubated ventilated COVID-19 patients.
- Conditions
- Prone Position, Severe Acute Respiratory Syndrome Coronavirus 2, Hypnotics and Sedatives, Pulmonary Ventilation
- Trial name
- NCT04667936
- Testing
- Treatment group
- Where
- Germany
- Volunteers
- 114 people
- Sponsor
- Goethe University
COVID-19
In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection
To estimate the pulmonary response microvascular thrombosis in critical patients due to SARS-Cov-2., at the Hospital General de México "Dr.
- Trial name
- NCT04926428
- Testing
- tPA
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Grupo Mexicano para el Estudio de la Medicina Intensiva
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
The purpose of this clinical trial is to determine the best initial non-invasive respiratory support (NIRS) strategy for adults who present to the emergency department with acute hypoxemic respiratory failure, a condition in…
- Trial name
- WINDSURFER (NCT07558265)
- Testing
- Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
- Where
- 6 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ohio State University
Covid-19, ARDS
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including…
- Conditions
- Covid-19, ARDS, Pneumonia
- Trial name
- NCT04365764
- Where
- 2 sites in France
- Volunteers
- 400 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
ARDS (Moderate or Severe)
Combining Electrical Impedance Tomography and Thoracic Ultrasound Toinvestigate Dynamic Changes
1. To evaluate the dynamic changes of lung ultrasound during electrical impedance tomography (EIT) PEEP titration and across the first week of ARDS. 2.
- Trial name
- NCT06958770
- Testing
- Electrical impedance tomography
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Medical Condition Requiring Extracorporeal Organ Support
The University of Freiburg Medical Center Extracorporeal Organ Support Device Registry
A prospective registry collecting pseudonymized clinical and treatment data from all patients treated with extracorporeal organ support (i.e., VV ECMO, VA ECMO, ECPR, Impella, IABP, and others) on the wards of the Department of…
- Trial name
- NCT05811780
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- University Hospital Freiburg
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection
An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications
This observational study will collect data from patients treated with siltuximab program for treatment of SARS-CoV-2 infection complicated with serious respiratory complications.
- Trial name
- SISCO (NCT04322188)
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Infant, Newborn, Hypertension, Pulmonary
Inhaled Nitric Oxide Study for Respiratory Failure in Newborns
Respiratory failure in term newborns is associated with increased rates of death and long-term neurodevelopmental problems. This large international multicenter trial randomized newborns who had failed to respond to intensive…
- Conditions
- Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration
- Trial name
- NINOS (NCT00005776)
- Testing
- Inhaled nitric oxide
- Where
- 20 sites in United States, Canada
- Volunteers
- 235 people
- Sponsor
- NICHD Neonatal Research Network
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.